Drug profile · INN
medrysone
HMS
medrysone (HMS) is a glucocorticoid receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — medrysone
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
medrysone (HMS) is a glucocorticoid receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is medrysone?
medrysone (HMS) is a glucocorticoid receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for medrysone?
HMS is a marketed brand name for medrysone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of medrysone?
medrysone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.